Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 19 September 2012 | By Louise Zornoza,
In May 2011 Australia's Therapeutic Goods Administration (TGA) put in place a Biologicals Regulatory Framework to assess and regulate human tissue-based products. Until then, those products were either not regulated, regulated as drugs or devices, or exempt from certain parts of the Therapeutic Goods Act.
As part of the three year transition period, the TGA yesterday issued a notice to sponsors of biologicals that are currently supplied in Australia, but not currently included in the Australian Register of Therapeutic Goods (ARTG). These sponsors, which include tissue banks supplying bone, ocular, cardiovascular and other biological products, have until 30 November 2012 to submit an application for registration or risk losing the right to market as of 31 May 2014. The notice specifies that products marketed before 31 May 2011 with applications submitted by the 2012 deadline can remain on the market after the 2014 cutoff even if a final decision has not been taken by the TGA on the application.
Read all Breaking News from RegLink
Tags: Regulatory Framework, New Zealand, Latest News, australia, Biologics